Wang J H, Wang J H, Liu Y C, Chen Y S, Yen M Y, Wann S R, Cheng D L
Department of Internal Medicine, Veterans General Hospital, Kaohsiung, Taiwan R.O.C.
J Formos Med Assoc. 1994 Jul;93(7):642-4.
We report a 67-year-old male with pneumonia in which Chlamydia pneumoniae was identified by serologic studies as the causative agent. After initial treatment failure with amoxicillin + clavulanic acid, pneumonia was successfully treated with the administration of oral azithromycin, 500 mg per day, for three days. Azithromycin is a new macrolide which has a long half-life and superior action to erythromycin. It provides a new and alternative choice in the treatment of Chlamydia pneumoniae infection in the future.
我们报告了一名67岁男性肺炎患者,血清学研究确定肺炎衣原体为病原体。在阿莫西林+克拉维酸初始治疗失败后,口服阿奇霉素(每天500毫克,共三天)成功治愈了肺炎。阿奇霉素是一种新型大环内酯类药物,半衰期长,作用优于红霉素。它为未来肺炎衣原体感染的治疗提供了一种新的替代选择。